sermorelin peptide vs bpc 157 What to know: the 4 peptides FDA just cleared Sermorelin vs BPC-157: Which Peptide

Patients with pre-existing peripheral neuropathy might report changes in sensation during treatment

The barrier will still be an investigational new drug application in an FDA designated disease indication (of which for many of these peptide use cases, there isn't one)

At 10mg/ml, even a small misread of the syringe changes your dose significantly

The medication's effects are generally dose-dependent, though the optimal dose should be determined based on both efficacy and tolerability

When counseling patients, its helpful to contextualize risk: emphasize that most adverse effects are mild and short-lived, but that serious complications, although rare, can occur without proper screening

Get in touch to book today